#Denmark #Lundbeck #Valby #Vyepti #RevenueGrowth

Lundbeck's Financial Performance

Lundbeck has recently announced a significant increase in its full-year guidance following a strong revenue growth in the first nine months of 2026. Total revenue rose by an impressive 13% at constant exchange rates (CER), amounting to DKK 20,191 million. This increase reflects contributions from all key global markets, showcasing the company's solid performance across various regions.

The primary driver of this growth is attributed to Vyepti®, Lundbeck's leading product for migraine treatment, which exhibited a staggering 45% increase in revenue. It generated DKK 4,533 million, showcasing both its popularity and the company's effective marketing strategies. Furthermore, Rexulti®, another key product, continued to perform well, bringing in DKK 5,071 million, with a growth of 13% at CER. This impressive revenue growth emphasizes Lundbeck's focus on maintaining a robust portfolio.

The company's operational strategy has transitioned into a partnership model across 27 markets, a move aimed at optimizing its market presence and enhancing revenue streams. This strategic shift has shown promising returns, as observed in the underlying revenue growth, which increased by an estimated 11% when adjusting for a one-time inventory build in the first quarter of 2026.

Regional Breakdown of Growth

• - United States: Contributed a significant DKK 11,217 million, marking an 18% increase at CER.
• - Europe: Generated DKK 4,714 million, with a 9% growth at CER, although the underlying growth was somewhat subdued at 3%.
• - International Operations: Reported DKK 4,000 million, reflecting a 5% increase at CER.

Across its strategic brands, Lundbeck reported an overall 16% growth at CER, confirming the efficacy of its focused commercial execution. Notably, Vyepti® emerges as a flagship product, directly influencing both the revenue trajectory and overall company outlook.

Financial Metrics Highlights

For the first nine months, Lundbeck reported an EBITDA of DKK 6,854 million, reflecting a 17% uptick at CER. Adjusted EBITDA also saw a significant rise, hitting DKK 7,026 million or a 19% increase at CER. These results include a one-time gross profit impact resulting from the transition to its partnership model. Excluding this impact, EBITDA grew by a solid 10%, demonstrating operational efficiency and effective cost management.

Earnings per share (EPS) also illustrated strong business momentum, reaching DKK 4.11, which is a 30% increase compared to the previous year. Adjusted EPS saw a 25% increase to DKK 5.42.

Strategic Vision and Future Outlook

Given the current momentum led by Vyepti®, Lundbeck's President and CEO, Charl van Zyl, expressed confidence in the company’s trajectory, announcing an upward revision in revenue expectations. The forecast for total revenue growth now sits between 11% and 12% at CER, while adjusted EBITDA is expected to grow by 15% to 19%.

Upcoming milestones, including the approval of Vyepti® in Japan, seem to bolster the company's global migraine treatment franchise further. As Lundbeck gears up for 2027, the company also aims to execute its Focused Innovator Strategy, which will serve as a crucial stepping stone toward enhancing innovation and addressing future market challenges.

In summary, Lundbeck showcases a strong financial performance with its strategic initiatives beginning to pay off. The robust sales growth driven by Vyepti® underlines the potential of Lundbeck's pipeline products and its commitment to improving healthcare solutions for patients worldwide.